AI-assisted international press reviewPress review

VINCI Launches a €600 Million Share Buyback Program

VINCI accelerates its share buyback program: signing an agreement to acquire up to €600 million in shares from January 6 to March 25, 2026, adhering to the price limits set by the shareholders' meeting. A bold financial strategy to strengthen its position in the markets.

Source: Vinci, published under the title "Implementation of the share buyback programme" - 6 January 2026

RegulationsAsia

India: A Bill to Regulate Seed Quality and Traceability

The Ministry of Agriculture is set to replace the 1966 law to ensure quality seeds, enhance traceability, and combat fraudulent sales. With over 9,500 comments analyzed, this reform aims to encourage innovation, protect farmers, and modernize a sector valued at $3.82 billion, while imposing severe penalties for major violations.

Source: Agropages, published under the title "Government of India to introduce seed bill in budget session" - 5 January 2026

EagleNXT Sells eBee TAC Drones to U.S. Army for Tactical Mapping

EagleNXT, a provider of advanced drone solutions, has announced the sale of six eBee TAC drones to the U.S. Army, each equipped with cutting-edge sensors for tactical mapping missions. This transaction, conducted through partner Dronivo, highlights the growing demand for accurate and reliable aerial data collection capabilities, essential for various military operations. The drones, optimized for challenging environments, offer unprecedented mapping accuracy, further strengthening EagleNXT's position in the defense market.

Source: Ageagle Aerial Systems, published under the title "EagleNXT Announces Successful Drone and Sensor Sale to U.S. ..." - 2 January 2026

Energy & Construction

Enel Celebrates the Energy of the Winter Olympics with New Campaign

As a premium partner of the Milano Cortina 2026 Winter Olympics and Paralympics, Enel launches an advertising campaign illustrating how energy, in all its forms, is essential to overcoming both sporting and personal challenges. The spot features a young skater facing obstacles, symbolizing the determination and resilience needed to achieve her goals. Launched on December 26, this campaign aims to inspire and motivate, highlighting that every challenge can become an opportunity for renewal.

Source: Enel, published under the title "Enel ignites the energy of the winter olympic games: the new..." - 2 January 2026

Mechanization & Robotics

CNH Strengthens Leadership Team with Two New Appointments

CNH (NYSE: CNH) has announced the appointment of Carlo Materazzo as Chief Manufacturing Officer and Britton Worthen as Chief Legal and Compliance Officer, effective January 1, 2026. These changes aim to support the company's commitment to operational excellence and innovation while enhancing governance. Materazzo, with 20 years of experience, will oversee global agricultural industrial operations, while Worthen will bring his expertise in legal strategy and compliance.

Source: Cnh, published under the title "CNH announces appointments to Global Leadership Team" - 2 January 2026

Flavors & Fragrances

TAKASAGO Releases Its 2025 Integrated Report in English Version

TAKASAGO announces the release of its 2025 Integrated Report, which outlines its Medium-Term Management Plan as well as its strategies in research, development, intellectual property, procurement, and supply chain management. This edition marks the first English version of the report, aimed at providing clear and relevant information about the company's activities.

Source: Takasago, published under the title "Integrated Report 2025 has been published" - 25 December 2025

Biotech & Genetics

AbacusBio and Bayer Extend Their Alliance Until 2030

AbacusBio and Bayer are extending their partnership, initially launched in 2020, to accelerate predictive plant breeding by integrating data science and farmer preferences.

Source: Agropages, published under the title "AbacusBio deepen strategic partnership with Bayer to pioneer..." - 23 December 2025

Guselkumab: First Approval for Pediatric Psoriasis in Europe

The European Commission's extension of the marketing authorization for TREMFYA® (guselkumab) marks a significant advancement in the treatment of moderate to severe plaque psoriasis in children and adolescents aged 6 and older. This approval, based on promising results from clinical studies, provides a new therapeutic option for a condition that profoundly impacts the quality of life of young patients.

Source: J&j - 23 December 2025

Investors

Vertical Agriculture in 2025: Funding Holds Steady, Caution Sets In

Indoor agriculture has attracted approximately $290 million in disclosed capital, with the majority of the 19 funding rounds occurring at Seed and Series B stages. This reflects a preference for companies refining their business models and developing technologies such as automation and data-driven climate control.

SEPEHR ACHARD, Source: Igronews, published under the title "Indoor Farming Funding in 2025: Where Capital Is Still Flowi..." - 23 December 2025

Mechanization & RoboticsSouth America

Embraer Conquers Latin America with Its Ethanol-Powered Agricultural Plane

Embraer certifies the Ipanema 203 in Paraguay, its ethanol agricultural aircraft, a leader in Brazil. With exceptional productivity – up to 200 hectares treated per hour – and advantages in efficiency, reduced costs, and sustainability, this aircraft enhances crop protection while promoting the adoption of renewable energies in intensive agriculture. A strategic step for Embraer and its entry into Latin American markets.

Source: Agropages, published under the title "Embraer's Ipanema 203 receives Paraguayan certification, lau..." - 23 December 2025

Biotech & Genetics

On the Trail of 'New GMOs': More Resilient and Climate-Adapted

New genetic editing techniques, more precise and 'natural' than traditional GMOs, aim to enhance crop resilience against climate change, drought, and diseases while reducing pesticide use. However, this innovative progress has sparked a heated debate in Europe over regulation, pitting proponents of easing restrictions against biodiversity advocates.

Source: Franceinfo, published under the title "Agriculture : la science sur la piste de "nouveaux OGM", plu..." - 23 December 2025

Biotech & GeneticsAsia

Vietnam Eases GMO Regulations Through Genetic Editing

Vietnam is amending the definition of genetically modified organisms (GMOs) in its biodiversity law to create a legal basis for excluding products developed through genetic editing, particularly those that do not contain foreign DNA, from the regulatory framework governing GMOs. The proposed amendment has been submitted to the National Assembly for review during its October 2025 session and is expected to take effect on January 1, 2026.

Source: Agropages, published under the title "Vietnam Ministry of Agriculture and Environment notifies dra..." - 23 December 2025

Finerenone Approved in Japan for Chronic Heart Failure

Finerenone has been approved in Japan for heart failure: a major therapeutic advance for patients with LVEF ≥40%. Based on positive results from the Phase III FINEARTS-HF study, presented at the ESC Congress 2024 and published in the New England Journal of Medicine, this non-steroidal drug targets the mineralocorticoid receptor to reduce cardiovascular events. Recommended as Class IIa by the 2025 Japanese guidelines, it fills a gap for the 1.2 million affected patients, offering new hope for cases of mildly reduced or preserved ejection fraction. Bayer thus strengthens its commitment to cardiology, with demonstrated clinical benefits in addition to existing treatments.

Source: Bayer, published under the title "Finerenone approved in Japan for treatment of patients with ..." - 22 December 2025

Pimicotinib: First Global Approval for TGCT in China

Pimicotinib represents a major advancement in oncology: the first global regulatory approval in China for treating rare tumors like TGCT. Based on the phase 3 MANEUVER study, it offers an impressive response rate of 54% at 25 weeks, significant improvements in mobility and quality of life, while remaining well tolerated. Merck thus strengthens its leadership, with regulatory filings underway elsewhere. A key milestone for patients!

Source: Merck, published under the title "Pimicotinib Approved as Systemic Treatment in China for Teno..." - 22 December 2025

Abbott Receives FDA Approval for Its Volt System Against Atrial Fibrillation

Abbott Volt PFA: A Revolution in Atrial Fibrillation Treatment. This innovative cardiac ablation technology uses targeted electrical pulses for a minimally invasive procedure, gentler on the heart. With reduced intervention times, improved recovery, and lasting results, it simplifies life for AFib patients, as confirmed by clinical studies. A breakthrough approved by the FDA for effective management of arrhythmias.

Source: Abbott, published under the title "Abbott's Volt™ Pulsed Field Ablation System Receives FDA App..." - 22 December 2025

Failure of LATIFY Treatment in Advanced Lung Oncology

The phase III LATIFY trial, evaluating the combination of ceralasertib and Imfinzi in patients with advanced non-small cell lung cancer, did not meet its primary endpoint of overall survival compared to standard treatment. Despite disappointing results, AstraZeneca remains committed to researching new therapies to improve outcomes for lung cancer patients.

Source: Astrazeneca, published under the title "Update on LATIFY Phase III trial of ceralasertib plus Imfinz..." - 22 December 2025

Enhertu: Breakthrough Therapy for HER2+ Breast Cancer in the USA

Major advancement in breast cancer treatment: AstraZeneca and Daiichi Sankyo receive the 10th breakthrough therapy designation for Enhertu, thanks to promising results from the DESTINY-Breast05 trial. This innovative drug targets HER2-positive patients at high risk of post-treatment recurrence, offering hope to reduce relapses and improve long-term prognoses. A key step towards more effective therapeutic options.

Source: Astrazeneca, published under the title "Enhertu granted Breakthrough Therapy Designation in the US a..." - 22 December 2025

Leighton Asia Wins Best Fundraising Trophy at the Lap Dog Challenge

Congratulations to the Leighton Asia team – Sean Angbuhang, Threwston Liu, Kenny Zeng, Vladimir Emmer, and Ronald Lam – for their epic achievement of 540 laps at the 10th anniversary of the Lap Dog Challenge in Hong Kong! This charity event brought together construction professionals to support the Lighthouse Club, the Hong Kong Breast Cancer Foundation, and the victims of the Tai Po fire. Proud to win the 'Best Fundraising' trophy, a symbol of our commitment to more sustainable communities. Thank you to our runners, supporters, and organizers for these solidarity laps!

Source: Cimic - 22 December 2025

Sanofi Lowers Drug Prices in the USA to Boost Innovation

Sanofi seals a historic agreement with the United States to reduce drug prices and boost innovation. Average savings of 61% on treatments for diabetes, cancer, and more, through platforms like TrumpRx.gov, while strengthening American manufacturing and investments. A major advancement for healthcare access and economic growth.

Source: Sanofi, published under the title "Press Release: Sanofi reaches agreement with the US governme..." - 20 December 2025

Novartis Commits to Reducing Drug Prices in the USA

Novartis has signed a major agreement with the United States to lower prices on innovative drugs and boost investments in R&D and manufacturing. The company pledges to expand access through direct platforms and support pharmaceutical innovation while maintaining its global commitments. A decisive step towards more equitable healthcare access.

Source: Novartis, published under the title "Novartis and US government reach agreement on lowering drug ..." - 20 December 2025